Shows
Few & Far Between: Conversations from the Front Lines of Drug DevelopmentEpisode 52: Joshua Kresh, Emily Michiko Morris, and Mark Schultz, IPPIHow does a biotech balance great science with IP security to tell their story? Find out on today's episode of the Few & Far Between podcast!
Host Chris O'Brien welcomes Joshua Kresh, Emily Michiko Morris, and Mark Schultz from IPPI: The Intellectual Property Policy Institute. Tune in for a fascinating discussion on the dos and don'ts of IP protection.
Listen to the latest episode today!2025-04-2352 min
FedSoc ForumsDoes Jarkesy Doom the Preserve Access to Affordable Generics and Biosimilars Act?Reducing the cost of prescription drugs has been a bipartisan priority for years. One recent effort is the Preserve Access to Affordadble Generics and Biosimilars Act (S. 142), sponsored by Sen. Klobuchar with the support of Sen. Grassley and others. This bill would give the FTC new authority to investigate settlements between branded and generic drug companies that delay generic/biosimilar market entry and are deemed anticompetitive. The bill proposes allowing the FTC to make factual findings and liability determinations that the district court applies when computing damages. Our expert panel will discuss whether this bifurcated administrative/judicial arrangement can be...2024-11-2653 min